According to recent reports by WHO, there are 2,303,312 COVID-19 infected persons around the world, with 270,765 deaths. Researchers and health experts around the globe are ardently focused on studying the novel coronavirus, where new findings and understanding help in the

The vaccine will be developed using the virus strain isolated at the ICMR#39;s National Institute of Virology (NIV), Pune, a statement said.

1. India's research body partners with vaccine manufacturing company to develop indigenous vaccine for COVID-19  China.org.cn
2. India to develop ‘fully indigenous’ Covid vaccine as ICMR partners with Bharat Biotech  ThePrint
3. ICMR teams up with Bharat Biotech to develop Covid-19 vaccine  Times of India
4. ICMR partners with Bharat Biotech to develop an indigenous coronavirus vaccine  Times Now
5. ICMR joins with Hyderabad firm to develop COVID-19 vaccine  Northeast Now
6. View Full coverage on Google News

Would a vaccine for the new coronavirus wind up offering long-lasting immunity? Or will the virus prove to be a shape-shifter, mutating quickly enough that people need annual vaccines like those for seasonal strains of influenza? Researchers are probing for answers in the rush to develop a vaccine for COVID-19.

The Indian and American pharmaceutical companies are currently working together on at least three possible vaccines to fight the coronavirus, India Ambassador to the United States, Taranjit Singh...

IIL is already working with Griffith University for conducting R&D of Zika virus vaccine which is currently at pre-clinical toxicology testing stage.

Israel has just reported a potent monoclonal antibody (mAb) against SARS CoV-2. Firms in South Korea, the US are leading mAb trials.

With more than 49,000 positive Coronavirus cases in India, rolling out a vaccine has become a key focus for Indian scientists and researchers.

The scientists tested their vaccine on mice. The mice developed antibodies immediately after a single injection, which prevented the virus from infecting human cells. Researchers selected 2 of the five candidates for the vaccine after studying them with the best results.

Coronavirus COVID 19 vaccine news, latest update, human trials: Sanofi's Pasteur division has an established track record in influenza vaccines. Last month it had teamed with its British rival GSK to produce a vaccine candidate hoping that it will be ready in 2021.

In the age of social media, digital technology, IoT and 3D printers, it is difficult for a lot of people to understand the delays in creation of a vaccine for the new disease.

Ambassador Sandhu also expressed some of the cooperation the US government has shown in the evacuation effort by the Indian government for its citizens stranded in the US post the lockdown across the world.

Health Minister David Clark has rejected claims he and other Government ministers have been "gagged", as he fronted today to announce a $160 million boost to Pharmac health spending.An email from the Prime Minister's office, obtained...

Washington: Orders for vaccines against diseases such as measles have declined since a national emergency was declared in the United States because of the coronavirus pandemic, the US Centers for Disease Control and Prevention said Friday.The number of vaccine doses ordered around the country has...

Dr. Vin Gupta joins to answer some practical questions about how effective the coronavirus tests really are and when we could really see a successful vaccine.

ZYUS Life Sciences is working with VIDO-InterVac to see if proteins produced by plants can be made into a working COVID-19 vaccine. 

Ministry of Science and Technology's Department of Biotechnology (DBT) Dr Renu Swarup says that based on the latest WHO consensus, Covid-19 as a 'lab release' theory is likely to be false.

Ministry of Science and Technology's Department of Biotechnology (DBT) Dr Renu Swarup says that based on the latest WHO consensus, Covid-19 as a 'lab release' theory is likely to be false.

1. ICMR, National Institute Of Virology Join Hands With Hyderabad Based Biotech Firm To Develop COVID-19 Vaccine  Swarajya
2. India to develop ‘fully indigenous’ Covid vaccine as ICMR partners with Bharat Biotech  ThePrint
3. ICMR teams up with Bharat Biotech to develop Covid-19 vaccine  Times of India
4. ICMR joins with Hyderabad firm to develop COVID-19 vaccine  Northeast Now
5. Covid-19 patients with mild symptoms don't need hospitalization: Health ministry's revised discharge policy  Livemint
6. View Full coverage on Google News

Washington (AFP) - Orders for vaccines against diseases such as measles have declined since a national emergency was declared in the United States because of the coronavirus pandemic, the US Centers for Disease Control and Prevention said Friday.

An experimental vaccine provided 100 percent protection against the mosquito-borne chikungunya virus in primates and mice, offering hope it will work for humans too, according to a study.

A new method of vaccine creation for Chikungunya virus (CHIKV) using a technique called large scale random codon re-encoding was developed by researchers.

High-resolution pictures or atomic-level detail of chikungunya virus interacting with a protein found on the cell surface in the joints was snapped by

Deliberately infecting volunteers could accelerate research but raises ethical questions

Cadila Pharmaceutical will seek the govt's nod in two days for initiating clinical trials for a vaccine against swine flu.

Ministry of Science and Technology's Department of Biotechnology (DBT) Dr Renu Swarup says that based on the latest WHO consensus, Covid-19 as a 'lab release' theory is likely to be false.

Washington, May 4: President Donald Trump says he believes a vaccine for COVID-19 will be available by the end of the year. Trump also says the U.S. government is putting its "full power and might" behind remdesivir, a drug that has

Washington, May 4: Hundreds of people are rolling up their sleeves in countries across the world to be injected with experimental vaccines that might stop COVID-19, spurring hope - maybe unrealistic - that an end to the pandemic may arrive sooner

Washington, May 05: President Donald Trump says he believes a vaccine for COVID-19 will be available by the end of the year. Trump also says the US government is putting its full power and might behind remdesivir, a drug that has

COVID-19 is currently the biggest, health and economic threat to the world. Researchers and scientists across the world are constantly making efforts to find its treatment and develop a vaccine to combat it. The biggest challenge in developing the vaccine

World Immunization Week is celebrated in the last week of April (24 to 30 April). Its main objective is to encourage the use of vaccines to protect people of all ages against diseases. Globally, Immunisation is considered a cost-effective public health

According to recent reports by WHO, there are 2,303,312 COVID-19 infected persons around the world, with 270,765 deaths. Researchers and health experts around the globe are ardently focused on studying the novel coronavirus, where new findings and understanding help in the

Work on vaccine development has been initiated between the two partners.

ICMR partners with BBIL for developing indigenous coronavirus vaccine

Djoko will need vaccine if required: Nadal

Pfizer and German partner BioNTech SE (22UAy.F) said on Tuesday they have begun delivering doses of their coronavirus vaccine candidates for initial human testing in the United States.

The vaccine will be developed using the virus strain isolated at the ICMR's National Institute of Virology (NIV), Pune, a statement said.

5 groups set up in National Task Force

Virus strain from NIV Pune transferred.

Source: Streetwise Reports   05/06/2020

In a May 4 research note, H.C. Wainwright & Co. analyst Ed Arce reported that Arcturus Therapeutics Holdings Inc. (ARCT:NASDAQ) formed a partnership with Catalent Inc. (CTLT:NYSE), which "raises the profile of LUNAR-COV19 as a leading vaccine candidate."

Arce reviewed Catalent's contribution to the partnership. The global contract development and manufacturing organization is to manufacture Arcturus' messenger RNA (mRNA) LUNAR-COV19 for protection against SARS-CoV-2 to be used first for human clinical trials and potentially, eventually commercially.

As for timing, Arce noted, San Diego, Calif.-based Arcturus intends to transfer its vaccine technology to Catalent this month and expects Catalent to manufacture the first batches of LUNAR-COV19 by June 2020. "Critically, Arcturus continues to anticipate initiation of Phase 1 testing of LUNAR-COV19 in the summer of 2020," Arce highlighted.

Catalent is to produce the vaccine at its biomanufacturing facility in Madison, Wisc. "This facility utilizes Catalent's flex-suite, a current good manufacturing practice manufacturing suite, that can produce batches at multiple scales and support Arcturus' proprietary mRNA manufacturing process," explained Arce.

Obtaining the vaccine from one facility domestically versus multiple entities worldwide should result in several benefits, Arce continued. They include easy development and production, accelerated delivery and improved costs. Arcturus believes Catalent can produce millions of doses of LUNAR-COV19 mRNA in 2020 and, if need be, hundreds of millions of doses each year subsequently for use globally.

Arce pointed out that LUNAR-COV19 differentiates itself from other similar vaccine candidates in that the technology and delivery platform behind it deliver an "extraordinarily low dose (perhaps 2 micrograms)" in "a potential single shot."

H.C. Wainwright has a Buy rating and a $62 per share price target on Arcturus, the stock of which is currently trading at about $42.12 per share.

Disclosure:
1) Doresa Banning compiled this article for Streetwise Reports LLC and provides services to Streetwise Reports as an independent contractor. She or members of her household own securities of the following companies mentioned in the article: None. She or members of her household are paid by the following companies mentioned in this article: None.
2) The following companies mentioned in this article are billboard sponsors of Streetwise Reports: None. Click here for important disclosures about sponsor fees.
3) Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
4) The article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. This article is not a solicitation for investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.
5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the interview or the decision to write an article until three business days after the publication of the interview or article. The foregoing prohibition does not apply to articles that in substance only restate previously published company releases.
6) This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.

Disclosures from H.C. Wainwright & Co., Arcturus Therapeutics Holdings Inc., First Take, May 4, 2020

Investment Banking Services include, but are not limited to, acting as a manager/co-manager in the underwriting or placement of securities, acting as financial advisor, and/or providing corporate finance or capital markets-related services to a company or one of its affiliates or subsidiaries within the past 12 months.

I, Ed Arce, certify that 1) all of the views expressed in this report accurately reflect my personal views about any and all subject securities or issuers discussed; and 2) no part of my compensation was, is, or will be directly or indirectly related to the specific recommendation or views expressed in this research report; and 3) neither myself nor any members of my household is an officer, director or advisory board member of these companies.

None of the research analysts or the research analyst's household has a financial interest in the securities of Arcturus Therapeutics Holdings Inc. (including, without limitation, any option, right, warrant, future, long or short position).

As of April 30, 2020 neither the Firm nor its affiliates beneficially own 1% or more of any class of common equity securities of Arcturus Therapeutics Holdings Inc.

Neither the research analyst nor the Firm has any material conflict of interest in of which the research analyst knows or has reason to know at the time of publication of this research report.

The research analyst principally responsible for preparation of the report does not receive compensation that is based upon any specific investment banking services or transaction but is compensated based on factors including total revenue and profitability of the Firm, a substantial portion of which is derived from investment banking services.

The firm or its affiliates received compensation from Arcturus Therapeutics Holdings Inc. for non-investment banking services in the previous 12 months.

The Firm or its affiliates did receive compensation from Arcturus Therapeutics Holdings Inc. for investment banking services within twelve months before, and will seek compensation from the companies mentioned in this report for investment banking services within three months following publication of the research report.

H.C. Wainwright & Co., LLC managed or co-managed a public offering of securities for Arcturus Therapeutics Holdings Inc. during the past 12 months.

The Firm does not make a market in Arcturus Therapeutics Holdings Inc. as of the date of this research report.

H.C. Wainwright & Co., LLC and its affiliates, officers, directors, and employees, excluding its analysts, will from time to time have long or short positions in, act as principal in, and buy or sell, the securities or derivatives (including options and warrants) thereof of covered companies referred to in this research report.

( Companies Mentioned: ARCT:NASDAQ, )

Scientific evidence is insufficient to prove or disprove the theory that exposure to polio vaccine contaminated with a monkey virus between 1955 and 1963 has triggered cancer in humans, says a new report from the Institute of Medicine of the National Academies.

The evidence does not support a causal link between sudden infant death syndrome (SIDS) and either the diphtheria, tetanus, and whole-cell pertussis (DTwP) vaccine or exposure to multiple childhood vaccines, says a new report from the Institute of Medicine of the National Academies.

Based on a thorough review of clinical and epidemiological studies, neither the mercury-based vaccine preservative thimerosal nor the measles-mumps-rubella (MMR) vaccine are associated with autism, says a new report from the Institute of Medicine of the National Academies.

Good afternoon. On behalf of the Institute of Medicine and the entire committee, I would like to welcome reporters and guests to the release of our report, Vaccines and Autism.